By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1020 Stony Hill Road
Suite 300
Yardley  Pennsylvania  19067  U.S.A.
Phone: 609-730-7500 Fax: 609-730-7501



Company News
Medivir AB (MVIRb.F)’s Partner Tibotec Announced that Final SVR24 Results from Phase IIb PILLAR Study of TMC435 will be Presented at the AASLD Meeting Today 11/7/2011 7:30:41 AM
Gilead Sciences, Inc. (GILD), Johnson & Johnson (JNJ)'s Tibotec Unit to Develop Combination HIV Drug 6/28/2011 7:45:38 AM
FDA Approves Tibotec's New HIV Treatment, Edurant 5/20/2011 10:28:49 AM
Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL 3/29/2011 7:10:22 AM
Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV 2/18/2011 6:35:14 AM
Tibotec: Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 9/21/2010 9:41:05 AM
Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 6/18/2009 8:34:26 AM